2025-522448-41-00Not yet recruitingPhase 2
OmaMig Pilot
OmaMig Pilot: An open-label, phase IIa, single arm pilot study evaluating the potential clinical benefit and safety of omalizumab in adults with episodic migraine.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 31 Mar 2026
Brief summary (registry, in English)
Evaluate the potential clinical benefit on monthly migraine days.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 28 Nov 2025
- Start date
- 1 Jan 2026
- Lead sponsor
- Oslo University Hospital HF
- Diseases
- Migraine
- EU CT number
- 2025-522448-41-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 25
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Having tried ≥ 3 prophylactic drugs against migraine during the last 10 years.
Other
- Use of other migraine preventives during the study.
- Interval headache not distinguishable from migraine.
- Breastfeeding or pregnancy
Who the study is looking for
- Adults with episodic migraine and 4–14 migraine days pr month with or without aura according to the International Classification of Headache Disorders (ICHD-3)
Age in the registry: 18 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oslo Universitetssykehus HF | Oslo | Norway | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.